CN108135985A - 癌症中的“免疫检查点干预” - Google Patents

癌症中的“免疫检查点干预” Download PDF

Info

Publication number
CN108135985A
CN108135985A CN201680052459.3A CN201680052459A CN108135985A CN 108135985 A CN108135985 A CN 108135985A CN 201680052459 A CN201680052459 A CN 201680052459A CN 108135985 A CN108135985 A CN 108135985A
Authority
CN
China
Prior art keywords
cancer
immune checkpoint
subject
clonal
neoantigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680052459.3A
Other languages
English (en)
Chinese (zh)
Inventor
N.麦格拉纳汉
R.罗森塔尔
C.斯旺顿
K.佩格斯
S.奎扎达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Priority to CN202510825270.4A priority Critical patent/CN120624654A/zh
Publication of CN108135985A publication Critical patent/CN108135985A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
CN201680052459.3A 2015-09-10 2016-09-12 癌症中的“免疫检查点干预” Pending CN108135985A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510825270.4A CN120624654A (zh) 2015-09-10 2016-09-12 癌症中的“免疫检查点干预”

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1516047.6A GB201516047D0 (en) 2015-09-10 2015-09-10 Method
GB1516047.6 2015-09-10
PCT/EP2016/071471 WO2017042394A1 (en) 2015-09-10 2016-09-12 "immune checkpoint intervention" in cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510825270.4A Division CN120624654A (zh) 2015-09-10 2016-09-12 癌症中的“免疫检查点干预”

Publications (1)

Publication Number Publication Date
CN108135985A true CN108135985A (zh) 2018-06-08

Family

ID=54362973

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680052459.3A Pending CN108135985A (zh) 2015-09-10 2016-09-12 癌症中的“免疫检查点干预”
CN202510825270.4A Pending CN120624654A (zh) 2015-09-10 2016-09-12 癌症中的“免疫检查点干预”

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510825270.4A Pending CN120624654A (zh) 2015-09-10 2016-09-12 癌症中的“免疫检查点干预”

Country Status (11)

Country Link
US (1) US11098121B2 (https=)
EP (1) EP3347039B1 (https=)
JP (1) JP7073254B2 (https=)
KR (1) KR20180081490A (https=)
CN (2) CN108135985A (https=)
AU (1) AU2016319316B2 (https=)
BR (1) BR112018004878B1 (https=)
CA (1) CA2997651A1 (https=)
GB (1) GB201516047D0 (https=)
RU (1) RU2739036C2 (https=)
WO (1) WO2017042394A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022141775A1 (zh) * 2021-01-04 2022-07-07 江苏先声医疗器械有限公司 基于dna甲基化谱的肿瘤免疫检查点抑制剂治疗有效性评估模型的构建方法

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
WO2011146632A1 (en) 2010-05-18 2011-11-24 Gene Security Network Inc. Methods for non-invasive prenatal ploidy calling
CN103608466B (zh) 2010-12-22 2020-09-18 纳特拉公司 非侵入性产前亲子鉴定方法
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
CN117467603A (zh) * 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) * 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス （アイピー） カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
AU2018298971B2 (en) 2017-07-14 2025-01-23 Cancer Research Technology Limited Analysis of HLA alleles in tumours and the uses thereof
WO2019016174A1 (en) * 2017-07-18 2019-01-24 Institut Gustave Roussy METHOD FOR ASSESSING RESPONSE TO TARGETING DRUG PD-1 / PDL-1 MEDICINES
JP7072825B2 (ja) * 2017-09-13 2022-05-23 三菱電機ソフトウエア株式会社 コピー数計測装置、コピー数計測プログラムおよびコピー数計測方法
USD844652S1 (en) * 2017-11-26 2019-04-02 Jan Magnus Edman Display screen with graphical user interface
WO2019109086A1 (en) * 2017-12-01 2019-06-06 Illumina, Inc. Methods and systems for determining somatic mutation clonality
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
CN112469730A (zh) * 2018-05-10 2021-03-09 加利福尼亚大学董事会 用于治疗癌症的ccl21和检查点抑制剂
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020033866A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
JP7623281B2 (ja) 2018-11-15 2025-01-28 パーソナル ゲノム ダイアグノスティクス インコーポレイテッド 免疫療法で治療されたがん患者の応答の予測を改善する方法
CN113692449A (zh) * 2018-12-21 2021-11-23 新加坡科技研究局 预测免疫检查点抑制疗法益处的方法
CN111383713B (zh) * 2018-12-29 2023-08-01 北京安诺优达医学检验实验室有限公司 ctDNA检测分析装置及方法
IL285155B2 (en) * 2019-01-28 2026-01-01 Univ Texas Therapy using metal chelators to treat cancer
EP3947737A2 (en) * 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020218322A1 (ja) * 2019-04-23 2020-10-29 国立大学法人東北大学 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
CN111394454B (zh) * 2020-01-06 2023-03-14 江苏省肿瘤防治研究所（江苏省肿瘤医院） 一种免疫相关生物标志物及其在头颈部鳞状细胞癌预后诊断中的应用
US20230037966A1 (en) * 2020-01-07 2023-02-09 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
JP7617574B2 (ja) * 2020-01-07 2025-01-20 コリア アドバンスド インスティテュート オブ サイエンス アンド テクノロジー 新生抗原をスクリーニングする方法、システム及びその用途
EP3868897A1 (en) * 2020-02-20 2021-08-25 Worldwide Innovative Network Method for improving the treatment with immune checkpoint blockade therapy
WO2022074648A1 (en) * 2020-10-05 2022-04-14 4C Biomed Limited Marker for response to pd-1/pd-l1 immunotherapy
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
JP7426165B2 (ja) * 2021-06-30 2024-02-01 ノバセラム株式会社 血中循環腫瘍細胞を含む試料を調製する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168874A2 (en) * 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7696487A (en) 1986-07-03 1988-01-29 Bio-Rad Laboratories, Inc. Peptide fragments of organ-specific neoantigens
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP2362882B1 (en) 2008-11-03 2016-01-27 Stichting Sanquin Bloedvoorziening Detecting antigen responsive cells in a sample
WO2010144192A1 (en) 2009-05-05 2010-12-16 Children's Medical Center Corporation Prognosis indicators for solid human tumors
US8176660B2 (en) 2009-07-30 2012-05-15 Nike, Inc. Customizable stud for an article of footwear
EP2482849B1 (en) 2009-09-30 2018-06-06 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2014012051A1 (en) 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
US20150197785A1 (en) 2012-08-10 2015-07-16 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
EP3330384B1 (en) 2012-10-01 2019-09-25 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2015014869A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
KR20230030022A (ko) 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
MY190083A (en) 2015-03-17 2022-03-25 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
US10597466B2 (en) 2015-12-02 2020-03-24 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
US11135221B2 (en) 2015-12-23 2021-10-05 Moonshot Pharma Llc Methods for inducing an immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168874A2 (en) * 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIMOTHY A YAP: "Intratumor heterogeneity：seeing the wood for the trees", 《SCI TRANSL MED》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022141775A1 (zh) * 2021-01-04 2022-07-07 江苏先声医疗器械有限公司 基于dna甲基化谱的肿瘤免疫检查点抑制剂治疗有效性评估模型的构建方法

Also Published As

Publication number Publication date
AU2016319316A1 (en) 2018-02-22
AU2016319316B2 (en) 2022-09-08
RU2018112516A (ru) 2019-10-10
RU2739036C2 (ru) 2020-12-21
KR20180081490A (ko) 2018-07-16
RU2018112516A3 (https=) 2020-02-10
EP3347039A1 (en) 2018-07-18
BR112018004878A2 (https=) 2018-10-02
BR112018004878B1 (pt) 2022-07-05
JP7073254B2 (ja) 2022-05-23
CN120624654A (zh) 2025-09-12
JP2018527935A (ja) 2018-09-27
US20180251553A1 (en) 2018-09-06
WO2017042394A1 (en) 2017-03-16
CA2997651A1 (en) 2017-03-16
GB201516047D0 (en) 2015-10-28
US11098121B2 (en) 2021-08-24
EP3347039B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
JP7073254B2 (ja) 癌における「免疫チェックポイント介入」
Gettinger et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
Braun et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
Losic et al. Intratumoral heterogeneity and clonal evolution in liver cancer
Clarke et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
Liu et al. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Kiyotani et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
Jia et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
Miao et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Havel et al. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jiménez-Sánchez et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient
Krysan et al. The immune contexture associates with the genomic landscape in lung adenomatous premalignancy
Lauss et al. Molecular patterns of resistance to immune checkpoint blockade in melanoma
US12331359B2 (en) Neoantigens and uses thereof for treating cancer
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
JP2020525030A (ja) 癌の免疫療法への適合性を評価する方法
WO2018102567A1 (en) Prediction of response to immune-modulatory therapies
Blanco-Heredia et al. Converging and evolving immuno-genomic routes toward immune escape in breast cancer
Willemsen et al. Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy
Xu et al. Zinc finger protein 296 promotes hepatocellular carcinoma progression via intervening interaction between macrophages and B cells
Yu et al. Spatially resolved whole-transcriptomic profiling of EGFR-mutated lung adenocarcinomas stratified by PD-L1 expression
Mohebalizadeh et al. Biomarkers for Monitoring the Immunotherapy Response to Cancer
Kaminska et al. Modeling anti-tumor immune responses using patient-derived melanoma organoids
HK1255677A1 (en) Immune checkpoint intervention in cancer
HK1255677B (en) Immune checkpoint intervention in cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240612

Address after: London

Applicant after: Achilles treatment UK Ltd.

Country or region after: Britain

Address before: London

Applicant before: CANCER RESEARCH TECHNOLOGY LTD.

Country or region before: Britain

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250512

Address after: American Maryland

Applicant after: MEDIMMUNE, LLC

Country or region after: U.S.A.

Address before: London

Applicant before: Achilles treatment UK Ltd.

Country or region before: Britain

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180608